Corvus Pharmaceuticals (CRVS) Competitors $3.52 -0.07 (-1.95%) Closing price 04:00 PM EasternExtended Trading$3.63 +0.11 (+3.15%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVS vs. COLL, MLYS, NTLA, SYRE, ZYME, RCUS, NRIX, CMRX, CDMO, and ELVNShould you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Collegium Pharmaceutical (COLL), Mineralys Therapeutics (MLYS), Intellia Therapeutics (NTLA), Spyre Therapeutics (SYRE), Zymeworks (ZYME), Arcus Biosciences (RCUS), Nurix Therapeutics (NRIX), Chimerix (CMRX), Avid Bioservices (CDMO), and Enliven Therapeutics (ELVN). These companies are all part of the "pharmaceutical products" industry. Corvus Pharmaceuticals vs. Collegium Pharmaceutical Mineralys Therapeutics Intellia Therapeutics Spyre Therapeutics Zymeworks Arcus Biosciences Nurix Therapeutics Chimerix Avid Bioservices Enliven Therapeutics Collegium Pharmaceutical (NASDAQ:COLL) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations. Which has more risk & volatility, COLL or CRVS? Collegium Pharmaceutical has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Do insiders and institutionals believe in COLL or CRVS? 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 2.5% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 31.3% of Corvus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor COLL or CRVS? In the previous week, Collegium Pharmaceutical had 3 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 6 mentions for Collegium Pharmaceutical and 3 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.17 beat Collegium Pharmaceutical's score of 1.05 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is COLL or CRVS more profitable? Collegium Pharmaceutical has a net margin of 14.78% compared to Corvus Pharmaceuticals' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 104.67% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Collegium Pharmaceutical14.78% 104.67% 18.38% Corvus Pharmaceuticals N/A -70.71%-45.90% Which has stronger valuation & earnings, COLL or CRVS? Collegium Pharmaceutical has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCollegium Pharmaceutical$631.45M1.38$48.15M$1.8614.55Corvus PharmaceuticalsN/AN/A-$27.03M-$0.97-3.63 Does the MarketBeat Community favor COLL or CRVS? Collegium Pharmaceutical received 98 more outperform votes than Corvus Pharmaceuticals when rated by MarketBeat users. Likewise, 65.49% of users gave Collegium Pharmaceutical an outperform vote while only 62.08% of users gave Corvus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCollegium PharmaceuticalOutperform Votes39165.49% Underperform Votes20634.51% Corvus PharmaceuticalsOutperform Votes29362.08% Underperform Votes17937.92% Do analysts rate COLL or CRVS? Collegium Pharmaceutical currently has a consensus price target of $43.60, suggesting a potential upside of 61.12%. Corvus Pharmaceuticals has a consensus price target of $15.67, suggesting a potential upside of 345.08%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 SummaryCollegium Pharmaceutical beats Corvus Pharmaceuticals on 12 of the 18 factors compared between the two stocks. Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVS vs. The Competition Export to ExcelMetricCorvus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$239.84M$6.71B$5.48B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-3.787.3522.6018.54Price / SalesN/A241.21397.55103.37Price / CashN/A65.8538.1834.62Price / Book4.466.486.744.25Net Income-$27.03M$143.41M$3.22B$248.18M7 Day Performance-3.83%2.13%1.55%1.27%1 Month Performance11.04%7.02%4.04%3.78%1 Year Performance118.63%-2.68%15.63%5.28% Corvus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVSCorvus Pharmaceuticals2.5915 of 5 stars$3.52-1.9%$15.67+345.1%+131.6%$239.84MN/A-3.7830Upcoming EarningsNews CoveragePositive NewsCOLLCollegium Pharmaceutical4.0398 of 5 stars$26.91-0.4%$43.60+62.0%-26.9%$864.67M$631.45M11.60210Upcoming EarningsPositive NewsMLYSMineralys Therapeutics2.3831 of 5 stars$13.24-0.8%$33.00+149.2%+16.0%$858.96MN/A-3.6428Upcoming EarningsShort Interest ↑NTLAIntellia Therapeutics4.6011 of 5 stars$7.92+9.5%$36.68+363.2%-58.6%$819.86M$57.88M-1.46600Upcoming EarningsHigh Trading VolumeSYRESpyre Therapeutics1.9141 of 5 stars$13.57+7.1%$49.57+265.3%-53.9%$817.95M$890,000.00-1.82100Upcoming EarningsNews CoveragePositive NewsZYMEZymeworks2.7664 of 5 stars$11.75+1.9%$21.00+78.7%+51.6%$817.53M$76.30M-7.83460Upcoming EarningsAnalyst RevisionPositive NewsRCUSArcus Biosciences2.2783 of 5 stars$7.68-2.5%$30.25+293.9%-42.6%$807.46M$258M-2.44500Upcoming EarningsPositive NewsNRIXNurix Therapeutics1.9307 of 5 stars$10.55+3.0%$30.44+188.6%-4.1%$804.29M$56.42M-3.65300Analyst ForecastCMRXChimerix3.0034 of 5 stars$8.55-0.1%$8.53-0.1%N/A$801.56M$212,000.00-9.0990CDMOAvid Bioservices0.7355 of 5 stars$12.50+0.1%$12.25-2.0%+63.8%$799.18M$139.91M-5.23320High Trading VolumeELVNEnliven Therapeutics2.2596 of 5 stars$16.22-1.9%$40.33+148.7%+8.9%$794.85MN/A-8.5450News CoveragePositive News Related Companies and Tools Related Companies Collegium Pharmaceutical Alternatives Mineralys Therapeutics Alternatives Intellia Therapeutics Alternatives Spyre Therapeutics Alternatives Zymeworks Alternatives Arcus Biosciences Alternatives Nurix Therapeutics Alternatives Chimerix Alternatives Avid Bioservices Alternatives Enliven Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRVS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRVS Stock Free CRVS Stock Alerts